2cureX AB (publ) (STO:2CUREX)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.872
+0.072 (4.00%)
Jul 24, 2026, 4:23 PM CET
Market Cap59.72M -20.4%
Revenue (ttm)1.98M -49.7%
Net Income-26.35M
EPS-1.50
Shares Out 31.90M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,650
Open1.800
Previous Close1.800
Day's Range1.800 - 1.872
52-Week Range0.514 - 4.200
Beta3.04
Analystsn/a
Price Targetn/a
Earnings DateAug 27, 2026

About 2cureX AB

2cureX AB (publ) operates as a medical technology company in Europe. ts proprietary IndiTreat test family creates various three-dimensional tumoroids derived from fresh samples of colorectal cancer (CRC) tissue that has been obtained from an individual patient’s metastatic colorectal cancer. 2cureX AB (publ) was incorporated in 2006 and is based in Landskrona, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 14
Stock Exchange Nasdaq Stockholm
Ticker Symbol 2CUREX
Full Company Profile

Financial Performance

In 2023, 2cureX AB's revenue was 2.95 million, a decrease of -12.53% compared to the previous year's 3.37 million. Losses were -32.52 million, 9.23% more than in 2022.

Financial Statements

News

2cureX AB Transcript: Investor update

A strategic shift is underway toward a comprehensive precision medicine platform, leveraging tumor preservation, U.S. expansion, and key partnerships to drive growth. Regulatory advantages and data generation are central to value creation, with recurring revenue expected from a shared diagnostic platform.

2 months ago - Transcripts

2cureX AB Quarterly report: H2 2025

2cureX AB has published its H2 2025 quarterly earnings report on February 26, 2026.

5 months ago - Filings

2cureX AB Annual report: H2 2025

2cureX AB has published its H2 2025 annual report on February 26, 2026.

5 months ago - Filings

2cureX AB Quarterly report: H1 2025

2cureX AB has published its H1 2025 quarterly earnings report on August 21, 2025.

1 year ago - Filings